Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(26)00050-1
Affiliations:
11
Authors:
21
Go to article
Institutions Authors Share
IRCCS San Raffaele Hospital (HSR), Italy
12.500000
12.500000
 0.60
Vita-Salute San Raffaele University (UniSR), Italy
3.500000
 0.17
Veracyte, United States of America (USA)
2.000000
 0.10
Foundation Medicine, Inc., United States of America (USA)
1.500000
 0.07
Erasmus University Medical Center (Erasmus MC), Netherlands
1.000000
 0.05
State University of New York Upstate Medical University (SUNY Upstate Medical University), United States of America (USA)
0.500000
 0.02
Interested in Oncology and Carcinogenesis?